Insider trade

Officer sold ~$203K of ABT shares in the open market

Traded Nov 25, 2025 · Filed Nov 25, 2025

Abbott LaboratoriesABT

~$203K
Reported value · 1,586 sh @ $128.0218: 30K
Holds after · shares reported

Why it stands out

Abbott Laboratories's Senior Vice President sold $203K of Abbott Laboratories shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 25, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 25, 2025

Officer$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$203,043

Shares × reported transaction price

Timing vs results

41 days after results of Oct 15, 2025, 58 days before results of Jan 22, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Volt PFA System on Dec 19, 2025, 24 days after this trade.

Premarket approval (PMA): Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation. From openFDA. Dates only; no link between the two is implied

Source receipt

Record ID: 0002058129-25-000009
Filed / recorded: Nov 25, 2025, 9:17 PM UTC
Added to OQRO: Oct 2, 2026, 12:26 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: ABBOTT LABORATORIES
Issuer CIK: 1800
Ticker: ABT
Reporting person: Eric Shroff
Relationship: Officer
Officer title: Senior Vice President
Security: Common shares without par value
Table: Non-derivative (Table I)
Transaction date: Nov 25, 2025
Transaction code: S
Shares / units: 1,586
Price per share: $128.0218
Acquired / disposed: Disposed (D)
Shares owned after: 30,384
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.02 to $128.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.